Evidence map›Paper›PMID 41117360›Full record

ArticlemAbs2025

A unified topology-based classification of SARS-CoV-2 RBD neutralizing antibodies systematizes affinity trends across variants.

Luis Fernando Cofas-Vargas, Paola Mendoza-Espinosa, Fernando D Montalvo-Sandoval, Saumel Pérez-Rodríguez, Jesús Antonio Rauda-Ceja, Pablo Hernández-Peralta, Adrián Durán-Vargas, Mauricio A Trujillo-Roldán, Norma A Valdez-Cruz, Enrique García-Hernández

Abstract read
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luis Fernando Cofas-VargasInstituto de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, México.ORCID 0000-0001-5603-1437
Paola Mendoza-EspinosaInstituto de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, México.ORCID 0000-0003-1447-8040
Fernando D Montalvo-SandovalDepartamento de Bionanotecnología, Centro de Nanociencias y Nanotecnología, Baja California, México.ORCID 0009-0008-7114-4139
Saumel Pérez-RodríguezBollyky Laboratory, Division of Infectious Diseases and Geographic Medicine, Department of Medicine, School of Medicine, Stanford University, Palo Alto, CA, USA.ORCID 0000-0003-3852-008X
Jesús Antonio Rauda-CejaInstituto de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, México.ORCID 0009-0008-9283-7006
Pablo Hernández-PeraltaFacultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, México.ORCID 0000-0002-0399-3023
Adrián Durán-VargasInstituto de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, México.ORCID 0009-0007-8836-1765
Mauricio A Trujillo-RoldánDepartamento de Bionanotecnología, Centro de Nanociencias y Nanotecnología, Baja California, México.ORCID 0000-0002-7497-4452
Norma A Valdez-CruzDepartamento de Bionanotecnología, Centro de Nanociencias y Nanotecnología, Baja California, México.ORCID 0000-0002-8581-1173
Enrique García-HernándezInstituto de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, México.ORCID 0000-0003-4561-4973

Funding

Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica, Universidad Nacional Autónoma de México IN209624Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica, Universidad Nacional Autónoma de México IV201220Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI) MAT-R: CF-2023-I-1248Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI) NAV-C: CF-2023-I-1549
6 · The paper itself

Abstract

The receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein, responsible for engaging the hACE2 receptor, is the principal target of neutralizing antibodies (NAb). To better understand how viral evolution undermines NAb protection, we present a comprehensive, topology-based classification derived from 544 NAbs and 60 nanobody-RBD complex structures. Five major NAb classes, each subdivided into two subclasses, were defined by binding zone, angle of approach, hACE2 competition, and hotspot usage. A systematic mapping of NAb-antigen contacts revealed 91 recurrent hotspot residues, some of which remain fully conserved across all Omicron variants. Leveraging > 2,300 experimentally dissociation constants spanning the Wuhan strain and Omicron lineages, we conducted a comparative affinity analysis across subclasses. NAbs in classes 1-3, which overlap the receptor-binding site, show progressive loss of affinity against Omicron, with many failing to bind recent subvariants due to emergent steric clashes and limited affinity maturation against the ancestral Wuhan RBD. Nonetheless, cases of Abs exhibiting resilience to viral drift have been documented. In contrast, classes 4 and 5 maintain high affinity regardless of their initial affinity for parental strains. Contemporary in-silico epitope predictors captured only ~40% of experimentally defined hotspots, highlighting the need for structure-guided approaches. By introducing a refined topological segmentation of the RBD grounded in previously described but unsystematized regions, our classification captures a broad diversity of NAb binding modes and provides an integrative structural framework that harmonizes prior classification schemes, its relationship with circulating variants, and highlights conserved epitope features relevant to broad-spectrum vaccine and therapeutic NAb design.

Indexed as

Antibodies, NeutralizingAntibodies, ViralAntibody AffinityCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2EpitopesHumansProtein DomainsSingle-Domain AntibodiesACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralEpitopesSingle-Domain AntibodiesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Affinity evolutionantibody classificationepitope mappingneutralizing antibodiesreceptor binding domain

Identifiers

PMID41117360
PMCPMC12542604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.